Pimecrolimus

Calcineurin Inhibitor Immunosuppressant — DERMATOLOGICALS

Key facts

Pimecrolimus is an ofp drug in the Calcineurin Inhibitor Immunosuppressant class catalogued in DrugCentral. It was first approved by the FDA in 2001. Its mechanism of action is classified as Calcineurin Inhibitors. DrugCentral lists 6 molecular targets, including FKBP1A, Fkbp1a and IL2. Recorded indications include Atopic dermatitis and Intractable Eczema.

• Approval status: ofp (first approved 2001 by the FDA).
• Drug class: Calcineurin Inhibitor Immunosuppressant.
• Mechanism of action: Calcineurin Inhibitors.
• Molecular targets: FKBP1A, Fkbp1a, IL2 and IL5 (6 listed in DrugCentral).
• Indications: Atopic dermatitis and Intractable Eczema.
• ATC code: D11AH02 (Agents for dermatitis, excluding corticosteroids).
• Molecular formula: C43H68ClNO11; molecular weight 810.46 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Atopic dermatitis
• Intractable Eczema

Contraindications (12)

• Eczema herpeticum
• Herpes simplex
• Herpes zoster
• Immunosuppression
• Impetiginized atopic dermatitis
• Infectious mononucleosis
• Lymphadenopathy
• Netherton's syndrome
• Pre-Malignant Skin Lesion
• Varicella
• Verruca vulgaris
• Viral infection of skin

Mechanism & targets

• Mechanism of action (MoA): Calcineurin Inhibitors
• Established pharmacologic class: Calcineurin Inhibitor Immunosuppressant

Molecular targets (6)

Target	Gene	Action	Activity
Peptidyl-prolyl cis-trans isomerase FKBP1A	FKBP1A	inhibitor	Kd 9.00
Peptidyl-prolyl cis-trans isomerase FKBP1A	Fkbp1a	inhibitor	IC50 8.22
Interleukin-2	IL2	unknown	—
Interleukin-5	IL5	unknown	—
Interferon gamma	IFNG	unknown	—
Serine/threonine-protein phosphatase 2B catalytic subunit gamma isoform	PPP3CC	unknown	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2001-12-13	FDA	—	VALEANT BERMUDA

ATC classification

ATC code	Therapeutic hierarchy
D11AH02	DERMATOLOGICALS › OTHER DERMATOLOGICAL PREPARATIONS › OTHER DERMATOLOGICAL PREPARATIONS › Agents for dermatitis, excluding corticosteroids

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Dermatitis atopic	785.6
Drug ineffective	296.0
Pruritus	251.8
Eczema	239.1
Dry skin	213.4
Skin exfoliation	181.8
Rash	163.3
Sleep disorder due to a general medical condition	131.0
Treatment failure	119.5
Psoriasis	118.5
Skin fissures	95.0
Erythema	91.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Pimecrolimus is on its molecule page.

• Molecular formula: C₄₃H₆₈ClNO₁₁
• Molecular weight: 810.46 g/mol
• CAS number: 137071-32-0
• InChIKey: KASDHRXLYQOAKZ-XDSKOBMDSA-N
• PubChem CID: 6509979

CC[C@@H]1\C=C(C)\C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC1=O)C(\C)=C\[C@@H]1CC[C@H](Cl)[C@@H](C1)OC

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Pimecrolimus used for?

DrugCentral lists the following indications for Pimecrolimus: Atopic dermatitis and Intractable Eczema.

How does Pimecrolimus work?

Pimecrolimus is classified as Calcineurin Inhibitors; its molecular targets in DrugCentral include FKBP1A (inhibitor), Fkbp1a (inhibitor), IL2 and IL5.

When was Pimecrolimus first approved?

Pimecrolimus was first approved by the FDA in 2001.

What drug class does Pimecrolimus belong to?

Pimecrolimus is in the Calcineurin Inhibitor Immunosuppressant class.

What is the chemical formula of Pimecrolimus?

Pimecrolimus has the molecular formula C43H68ClNO11 and a molecular weight of 810.46 g/mol.

Sources

• DrugCentral drug card 2168 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200686 — compound record and bioactivity
• PubChem CID 6509979 — chemical identifiers
• DrugBank DB00337 — drug record
• FDA UNII 7KYV510875 — substance identity
• DailyMed: FDA labels for Pimecrolimus — current prescribing information (label search)
• UniProt P62942 (FKBP1A) — target protein
• UniProt P60568 (IL2) — target protein
• UniProt P05113 (IL5) — target protein
• UniProt P01579 (IFNG) — target protein
• UniProt P48454 (PPP3CC) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.